Evidence map›Paper›PMID 33294149›Full record

ArticleTherapeutic advances in chronic disease2020

Effectiveness and safety of methotrexate

Chunling Wu, Ying Sun, Xiaomeng Cui, Sifan Wu, Lili Ma, Huiyong Chen, Yan Yan, Zongfei Ji, Yun Liu, Jiang Lin and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in chronic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Chunling WuDepartment of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, P. R. China.
Ying SunDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0002-3004-0105
Xiaomeng CuiDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Sifan WuDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Lili MaDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Huiyong ChenDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Yan YanDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Zongfei JiDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Yun LiuDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Jiang LinDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Peng LvDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Rongyi ChenDepartment of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Pingting YangDepartment of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
Lindi JiangDepartment of Rheumatology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai, 200032, P. R. China Centre of Evidence-based Medicine, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0002-4326-6517
Fudan University · CNFirst Hospital of China Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe study investigates the effectiveness and safety of methotrexate (MTX)

methodsThis was a cohort study. Patients diagnosed with TAK between 1 January 2013 and 1 January 2019 were enrolled from First Hospital of China Medical University and Zhongshan Hospital of Fudan University. Patients had active disease and were treated with glucocorticoid combined with LEF or MTX. Treatment response, imaging assessment and side-effects were evaluated during 12-month follow-up.

resultsIn total, 68 patients were enrolled (40 cases treated with LEF and 28 treated with MTX). At baseline, age, sex, disease duration and disease activity index showed no significant differences between groups. Prevalence of complete remission (CR) at 6 months was significantly higher in the LEF group than that in the MTX group (LEF

conclusionLEF might provide a quicker treatment response with lower prevalence of disease relapse compared with that elicited in MTX during 12 months follow-up for TAK.

Indexed as

leflunomidemethotrexateside effectsTakayasu arteritistreatment response

Identifiers

PMID33294149
PMCPMC7705767
OpenAlexW3109906825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.